Akura Medical has secured a US$53 million first close in series C financing, with the funds to be used to support development activities for the Katana thrombectomy system and the NavIQ quantification software, alongside completion of enrolment in the QUADRA-PE clinical trial and regulatory submissions.
The financing round was led by Qatar Investment Authority (QIA) with participation by current investors. Part of the funds will be used to set up a joint venture in Qatar.
“Akura Medical is advancing a differentiated portfolio of venous thrombectomy technologies aimed at improving procedural precision and patient outcomes. The recent introduction of our NavIQ quantification software represents the next step toward intelligent, data-driven thrombectomy,” said Amr Salahieh, chair and acting chief executive officer of Akura Medical. “This new capital enables us to accelerate product development and continue building the foundation for long-term growth. We appreciate QIA’s confidence and partnership as we deliver on our vision.”
Akura Medical’s thrombectomy portfolio includes both the flagship Katana system and the NavIQ procedural planning software in development. The Katana system is an intelligent thrombectomy system designed to remove diverse clot types, optimise catheter delivery and provide supplementary intraoperative feedback.
The system leverages high velocity saline jets that are engineered to effectively break up clots independent of morphology and prevent catheter clogging for procedural efficiency. The system also incorporates sensors that provide real-time pulmonary artery pressure data to provide insights into procedure progress.
NavIQ is a quantification software that is designed to convert a CT angiogram into a 3D model of the pulmonary vasculature. The model is intended for use in anatomical visualisation of the arteries and clots to allow for pre-procedural planning. Additionally, NavIQ is designed to provide clot characterisation data to assist physicians with treatment prioritisation.
Akura Medical is a Shifamed portfolio company.
